Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis

Lilly J H Brada*, Lois A Daamen, Lisa G Magermans, Marieke S Walma, Diba Latifi, Ronald M van Dam, Ignace H de Hingh, Mike S L Liem, Vincent E de Meijer, Gijs A Patijn, Sebastiaan Festen, Martijn W J Stommel, Koop Bosscha, Marco B Polée, Yung C Nio, Frank J Wessels, Jan J J de Vries, Krijn P van Lienden, Rutger C Bruijnen, Olivier R BuschBas Groot Koerkamp, Casper van Eijck, Quintus I Molenaar, Hanneke J W Wilmink, Hjalmar C van Santvoort, Marc G Besselink*, Dutch Pancreatic Cancer Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)729-735
Number of pages7
JournalAnnals of Surgery
Volume274
Issue number5
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • Antineoplastic Agents/therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Female
  • Fluorouracil/therapeutic use
  • Follow-Up Studies
  • Humans
  • Irinotecan/therapeutic use
  • Leucovorin/therapeutic use
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Netherlands/epidemiology
  • Oxaliplatin/therapeutic use
  • Pancreas/pathology
  • Pancreatectomy/methods
  • Pancreatic Neoplasms/diagnosis
  • Propensity Score
  • Prospective Studies
  • Survival Rate/trends
  • SURGERY
  • FOLFIRINOX
  • locally advanced pancreatic cancer
  • QUALITY-OF-LIFE
  • BORDERLINE
  • ADENOCARCINOMA
  • NEOADJUVANT THERAPY
  • resection
  • IMPACT
  • OUTCOMES

Cite this